


SUPPLEMENT 1

a)



b)




Figure 1. Flowchart and number of participants of a) UTUC and b) urethral carcinoma included in the different forms of SNRUBC.

Table 1. Coding and morphology for cancer types included in the BladderBaSe 2.0

Cancer types	ICD-0-3 codes	Morphology	SNOMED codes
Urinary bladder cancer	C67.0-C67.6, C67.8, C67.9	Urothelial carcinoma Adenocarcinoma Squamous cell carcinoma Mucinous adenocarcinoma Adenosquamous carcinoma Neuroendocrine carcinoma Unspecified	81202, 81301, 81203, 812031, 812032, 812033, 81302, 813021, 813022, 813023, 81403, 80703, 81313, 81223, 80823, 80313, 80203, 80003, 84803, 85603, 80413, 80133, 82403
Upper tract urothelial carcinoma (UTUC) in the renal pelvis	C65.9	Urothelial carcinoma	81202, 81301, 81203, 812031, 812032, 812033, 81302, 813021, 813022, 813023
Upper tract urothelial carcinoma (UTUC) in the ureter	C66.9	Urothelial carcinoma	81202, 81301, 81203, 812031, 812032, 812033, 81302, 813021, 813022, 813023
Urethral carcinoma	C68.0	Urothelial carcinoma	81202, 81301, 81203, 812031, 812032, 812033, 81302, 813021, 813022, 813023

Table 2. Registered data on complications and re-operations recorded within 90 days after radical cystectomy in the radical cystectomy form in the SNRUBC and included in the BladderBaSe 2.0.

Gastrointestinal complications (recorded with date, re-operation, and Clavien score)
Postoperative intestinal obstruction
Anastomotic insufficiency
Intestinal fistula
Cardiovascular complications (recorded with date and Clavien score)
Deep vein thrombosis
Pulmonary embolism
Acute myocardial infarction
Cerebrovascular insult
Arterial thrombosis/emboli
Infectious complications (recorded with date and Clavien score)
Sepsis
Pneumonia
Pyelonephritis
Lymphocele
Other specific infectious complications
Abdominal wall/parastomal complications (recorded with date, re-operation, and Clavien score)
Wound infection
Subcutaneous wound dehiscence
Abdominal wall hernia
Other abdominal wall complications
Stoma necrosis
Urinary tract complications (recorded with date, re-operation, and Clavien score)
Ureteroenteric stenosis
Other urinary tract complications
Ureteroenteric anastomosis insufficiency
Enterourethral stricture neobladder
Bleeding (recorded with date, re-operation, and Clavien score)
Re-do surgery due to bleeding
Other complications (recorded with Clavien score)

Table 3. Variables, their options and proportions, and variable capture ratios in the standardized form for a) diagnosis and b) primary treatment of UTUC in the renal pelvis in the SNRUBC and included in the BladderBaSe 2.0

a) Variables from the diagnosis form of UTUC in the renal pelvis		
Variable	Options (proportions)	Recorded years: Capture ratio
Date of diagnosis	Date	2015-2019: 100%
Reporting date	Date	2015-2019: 100%
Side	Right: 48.8%	2015-2019: 100%
	Left: 51.5%	
	Missing: 0.1%	
County at diagnosis	Stockholm county: 19.8%	2015-2019: 100%
	Västra Götaland county: 17.8%	
	Skåne county: 14.4%	
	Östergötland county: 4.7%	
	Halland county: 4.4%	
	Örebro county: 3.6%	
	Jönköping county: 3.5%	
	Uppsala county: 3.2%	
	Västernorrland county: 3.1%	
Södermanland county: 3.0%		
Other: 22.4%		
Code for reporting hospital	Hospital codes	2015-2019: 99-100%
Healthcare Region	Stockholm/Gotland: 20.6%	2015-2019: 100%
	Uppsala/Örebro: 19.3%	
	South-East: 10.5%	
	South: 19.4%	
	West: 20.6%	
North: 9.5%		
Grade in three classes, GX set to missing	G1/LMP: 15.0%	2015-2019: 86-95%
	G2: 34.3%	
	G3-G4/anaplastic: 50.7%	
Date of referral	Date	2015-2019: 97-99%
Reason for referral	Referral registered: 67.4%	2015-2019: 99-100%
	Self-referral by patient: 20.2%	
	Other: 12.4%	
Date of referral registered	Date	2015-2019: 75-83%
Date of first visit to urologist	Date	2015-2019: 98-100%
Smoking status	Never smoker: 34.4%	2019: 81%
	Previous smoker: 39.3%	
	Current smoker: 26.4%	
Date of basis for diagnosis (below)	Date	2015-2019: 99-100%
Basis for diagnosis (several alternatives)	Computed tomography/MRI	Not applicable
	Retrograde or antegrade pyelography	
	Ureteropyeloscopy	
	Voided urinary cytology	
	Cytology obtained from renal pelvis or ureteric barbotage	
	Selective urinary cytology obtained from ureteric catheter	
	Biopsy obtained during ureteropyeloscopy	
Morphological diagnosis (SNOMED)	813033: 21.4%	2015-2019: 98-100%
	813022: 17.4%	
	812033: 17.1%	
	813021: 10.4%	
	813032: 8.9%	
	81203: 8.4%	

	813023: 6.2%	
	812032: 5.0%	
	81202: 2.2%	
	812031: 1.0%	
	Other: 2.1%	
Earlier/concomitant diagnosis (several alternatives)	No	Not applicable
	Urinary bladder cancer	
	UTUC in the ureter	
	UTUC in the renal pelvis, other side	
T stage (TNM-2017)	Urethral carcinoma	2015-2019: 96-100%
	Ta: 36.6%	
	Tis: 1.9%	
	T1: 12.0%	
	T2: 7.9%	
	T3: 26.9%	
N stage	T4: 7.3%	2015-2019: 98-100%
	TX: 7.5%	
	N0: 66.2%	
	N1: 6.7%	
	N2: 8.9%	
M stage	N3: 0.3%	2015-2019: 98-100%
	NX: 18.0%	
	M0: 89.1%	
	M1: 10.9%	

b) Variables from the primary treatment form of UTUC in the renal pelvis		
Variable	Options (proportions)	Recorded years: Capture ratio
Reporting date	Date	2015-2019: 95-99%
Code for reporting hospital	Hospital codes	2015-2019: 99-100%
Discussed at multidisciplinary conference	No: 38.6%	2015-2019: 98-100%
	Yes: 61.4%	
Additional treatment	No: 14.6%	2015-2019: 99-100%
	Yes: 85.4%	
Given treatment (several alternatives)	Nephroureterectomy (yes/no)	Not applicable
	Date of nephroureterectomy	
	Bladder cuff excised (yes/no)	
	Nephrectomy (yes/no)	
	Date of nephrectomy	
	Type of nephrectomy (open, robot, laparoscopy)	
	Local resection (yes/no)	
	Date of local resection	
	Type of local resection (open, robot, laparoscopy)	
	Endoluminal resection (yes/no)	
	Date of endoluminal resection	
	Endoluminal instillation BCG/chemotherapy (yes/no)	
	Date of local endoluminal instillation BCG/chemotherapy	
	Type of administration of endoluminal instillation (Nephrostomy/ Double-J/ Ureteric catheter)	
Treatment with curative intent	No: 13.5%	2015-2019: 99-100%
	Yes: 86.5%	

Table 4. Variables, their options and proportions, and variable capture ratios in the standardized form for a) diagnosis and b) primary treatment of UTUC in the ureter in the SNRUBC and included in the BladderBaSe 2.0

a) Variables from the diagnosis form of UTUC in the ureter		
Variable	Options (proportions)	Recorded years: Capture ratio
Side	Right: 48.9%	2015-2019: 100%
	Left: 50.7%	
	Missing: 0.4%	
Date of diagnosis	Date	2015-2019: 100%
Report date	Date	2015-2019: 100%
County at diagnosis	Stockholm county: 24.1%	2015-2019: 100%
	Skåne county: 17.8%	
	Västra Götaland county: 15.2%	
	Östergötland county: 4.5%	
	Jönköping county: 4.5%	
	Halland county: 3.7%	
	Västerbotten county: 3.7%	
	Kalmar county: 2.9%	
	Uppsala county: 2.6%	
	Kronoberg county: 2.6%	
Other: 18.3%		
Code for reporting hospital	Hospital codes	2015-2019: 100%
Healthcare Region	Stockholm/Gotland: 24.9%	2015-2019: 100%
	Uppsala/Örebro: 13.0%	
	South-East: 12.2%	
	South: 24.0%	
	West: 17.3%	
	North: 8.6%	
Grade in three classes, GX set to missing	G1/LMP: 22.4%	2015-2019: 90-96%
	G2: 31.1%	
	G3-G4/anaplastic: 46.5%	
Date of referral	Date	2015-2019: 92-99%
Reason for referral	Referral registered: 50.6%	2015-2019: 97-100%
	Self-referral by patient: 40.5%	
	Other: 8.9%	
Date of referral registered	Date	2015-2019: 53-67%
Date of first visit to urologist	Date	2015-2019: 97-99%
Smoking status	Never smoker: 27.5%	2019: 74%
	Previous smoker: 43.6%	
	Current smoker: 28.9%	
Date for basis for diagnosis (below)	Date	2015-2019: 98-100%
Basis for diagnosis (several alternatives)	Computed tomography/MRI	Not applicable
	Retrograde or antegrade pyelography	
	Ureteropyeloscopy	
	Voided urinary cytology	
	Cytology obtained from renal pelvis or ureteric barbotage	
	Selective urinary cytology obtained from ureteric catheter	
	Biopsy obtained during ureteropyeloscopy	
Morphological diagnosis (SNOMED)	813022: 18.3%	2015-2019: 99-100%
	813021: 16.9%	
	81202: 15.4%	
	813033: 12.6%	
	812033: 11.4%	
	813023: 7.9%	

	813032: 5.8%	
	812032: 4.6%	
	81203: 4.1%	
	81301: 1.6%	
	Other: 1.5%	
Earlier/concomitant diagnosis (several alternatives)	No	Not applicable
	Urinary bladder cancer	
	UTUC in the ureter, other side	
	UTUC in the renal pelvis	
	Urethral carcinoma	
T stage (TNM-2017)	Ta: 45.9%	2015-2019: 98-100%
	Tis: 14.4%	
	T1: 14.8%	
	T2: 9.0%	
	T3: 8.4%	
	T4: 1.4%	
	TX: 6.0%	
N stage	N0: 72.3%	2015-2019: 99-100%
	N1: 2.8%	
	N2: 3.2%	
	N3: 0.2%	
	NX: 21.4%	
M stage	M0: 95.8%	2015-2019: 99-100%
	M1: 4.2%	

b) Variables from the primary treatment form of UTUC in the ureter		
Variable	Options (proportions)	Recorded years: Capture ratio
Reporting date	Date	2015-2019: 95-100%
Code for reporting hospital	Hospital codes	2015-2019: 99-100%
Discussed at multidisciplinary conference	No: 35.4%	2015-2019: 84-93%
	Yes: 64.6%	
Additional treatment	No: 17.5%	2015-2019: 84-99%
	Yes: 82.5%	
Detected by cystectomy	No: 86.4%	2015-2016: 7-38%; 2017-2019: 98-100%
	Yes: 13.6%	
Given treatment (several alternatives)	Nephroureterectomy (yes/no)	Not applicable
	Date of Nephroureterectomy	
	Bladder cuff (yes/no)	
	Local resection (yes/no)	
	Date of local resection	
	Type of local resection (open/robot/laparoscopy)	
	Endoluminal resection (yes/no)	
	Date of endoluminal resection	
	Endoluminal instillation BCG/chemotherapy (yes/no)	
	Date of local endoluminal instillation BCG/chemotherapy	
	Type of local endoluminal instillation BCG/chemotherapy (nephrostomy/double-J/ureterary catheter)	
Treatment with curative intent	No: 12.9%	2015-2019: 97-100%
	Yes: 87.1%	

Table 5. Variables, their options and proportions, and variable capture ratios in the standardized form for a) diagnosis and b) primary treatment of urethral carcinoma in the SNRUBC and included in the BladderBaSe 2.0

a) Variables from the diagnosis form of urethral carcinoma		
Variable	Options (proportions)	Recorded years: Capture ratio
Date of diagnosis	Date	2015-2019: 100%
Reporting date	Date	2015-2019: 100%
County at diagnosis	Skåne county: 37.0%	2015-2019: 100%
	Stockholm county: 13.7%	
	Västra Götaland county: 12.3%	
	Norrbottnens county: 6.2%	
	Jämtlands county: 4.8%	
	Östergötland county: 4.1%	
	Jönköping county: 4.1%	
	Gävleborg county: 2.7%	
	Uppsala county: 2.1%	
Kronoberg county: 2.1%		
Other: 11.0%		
Code for reporting hospital	Hospital codes	2015-2019: 100%
Hospital region	Stockholm/Gotland: 13.7%	2015-2019: 100%
	Uppsala/Örebro: 8.9%	
	South-East: 10.3%	
	South: 41.1%	
	West: 12.3%	
Grade in three classes (GX set to missing)	G1/LMP: 15.6%	2015-2019: 86-94%
	G2: 15.6%	
	G3-G4/anaplastic: 68.9%	
Date of referral	Date	2015-2019: 66-100%
Reason for referral	Referral registered: 42.5%	2015-2019: 100%
	Self-referral by patient: 47.9%	
	Other: 9.6%	
Date of referral registered	Date	2015-2019: 36-66%
Date of first visit to urologist	Date	2015-2019: 96-100%
Smoking status	Never smoker: 26.3%	2019: 60%
	Previous smoker: 47.4%	
	Current smoker: 26.3%	
Date of basis for diagnosis (below)	Date	2015-2019: 100%
Basis for diagnosis (several alternatives)	Computed tomography/MRI	Not applicable
	Urethrocystoscopy	
	Voided urinary cytology	
	Cytology urethral barbotage	
	Urethral biopsy	
Morphological diagnosis (SNOMED)	81202: 29.0%	2015-2019: 93-100%
	812033: 17.9%	
	813022: 13.1%	
	813033: 11.7%	
	813021: 8.3%	
	813023: 8.3%	
	81203: 3.4%	
	81301: 2.8%	
	81302: 2.1%	
	812032: 1.4%	
	Other: 2.1%	
	No	Not applicable
	Urinary bladder cancer	

Earlier/concomitant diagnosis (several alternatives)	UTUC in the ureter	
	UTUC in the renal pelvis	
T stage (TNM-2017)	Ta: 36.1%	2015-2019: 96-100%
	Tis: 28.5%	
	T1: 15.3%	
	T2: 10.4%	
	T3: 2.8%	
	T4: 2.8%	
N stage	TX: 4.2%	2015-2019: 100%
	N0: 56.8%	
	N1: 1.4%	
	N2: 4.8%	
M stage	NX: 37.0%	2015-2019: 100%
	M0: 93.2%	
	M1: 6.8%	

b) Variables from the primary treatment form of urethral carcinoma		
Variable	Options (proportions)	Recorded years: Capture ratio
Reporting date	Date	2015-2019: 86-100%
Reporting hospital code	Hospital codes	2015-2019: 100%
Discussed at multidisciplinary conference	No: 33.8%	2015-2019: 91-100%
	Yes: 66.2%	
Additional treatment	No: 33.8%	2015-2019: 91-100%
	Yes: 66.2%	
Detected at cystectomy or in the cystectomy specimen	No: 94.3%	2015-2016: 19-61%; 2017-2019: 97-100%
	Yes: 5.7%	
Given treatment (several alternatives)	Cystectomy (yes/no)	NA
	Date of cystectomy	
	Type of cystectomy (open/robot)	
	Local resection (yes/no)	
	Date of local resection	
	Endoluminal resection (yes/no)	
Treatment with curative intent	No: 15.7	2015-2019: 97-100%
	Yes: 84.3%	

Table 6. Capture ratios of the different options in the standardized form for oncological treatment for bladder cancer, upper tract urothelial carcinoma (UTUC), or urethral carcinoma in the SNRUBC and included in the BladderBaSe 2.0. As comparison, we have used patients with diagnosis date in 2017 and later and systemic chemotherapy as primary treatment, separately for each cancer form.

Diagnosis	Diagnosis year	Neoadjuvant	Induction	Adjuvant	Palliative	Any
Bladder cancer	2017	62 (33,9 %)	10 (5,5 %)	2 (1,1 %)	34 (18,6 %)	95 (51,9 %)
	2018	72 (40,0 %)	22 (12,2 %)	4 (2,2 %)	38 (21,1 %)	126 (70,0 %)
	2019	58 (30,1 %)	14 (7,3 %)	0 (0,0 %)	42 (21,8 %)	108 (56,0 %)
	Total	192 (34,5 %)	46 (8,3 %)	6 (1,1 %)	114 (20,5 %)	329 (59,2 %)
UTUC in the renal pelvis	2017	0 (0,0 %)	2 (12,5 %)	1 (6,2 %)	5 (31,2 %)	8 (50,0 %)
	2018	0 (0,0 %)	2 (8,0 %)	1 (4,0 %)	8 (32,0 %)	11 (44,0 %)
	2019	0 (0,0 %)	1 (3,7 %)	1 (3,7 %)	5 (18,5 %)	7 (25,9 %)
	Total	0 (0,0 %)	5 (7,4 %)	3 (4,4 %)	18 (26,5 %)	26 (38,2 %)
UTUC in the ureter	2017	0 (0,0 %)	1 (11,1 %)	1 (11,1 %)	1 (11,1 %)	3 (33,3 %)
	2018	0 (0,0 %)	2 (14,3 %)	3 (21,4 %)	2 (14,3 %)	7 (50,0 %)
	2019	0 (0,0 %)	0 (0,0 %)	1 (9,1 %)	2 (18,2 %)	3 (27,3 %)
	Total	0 (0,0 %)	3 (8,8 %)	5 (14,7 %)	5 (14,7 %)	13 (38,2 %)
Urethral carcinoma	2017	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)
	2018	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)	0 (0,0 %)
	2019	1 (25,0 %)	0 (0,0 %)	0 (0,0 %)	1 (25,0 %)	2 (50,0 %)
	Total	1 (10,0 %)	0 (0,0 %)	0 (0,0 %)	1 (10,0 %)	2 (20,0 %)
Total	2017	62 (29,1 %)	13 (6,1 %)	4 (1,9 %)	40 (18,8 %)	106 (49,8 %)
	2018	72 (32,7 %)	26 (11,8 %)	8 (3,6 %)	48 (21,8 %)	144 (65,5 %)
	2019	59 (25,1 %)	15 (6,4 %)	2 (0,9 %)	50 (21,3 %)	120 (51,1 %)
	Total	193 (28,9 %)	54 (8,1 %)	14 (2,1 %)	138 (20,7 %)	370 (55,4 %)

Table 7. Registered data in the oncology form in the SNRUBC and included in the BladderBaSe 2.0.

General information
Date of cancer diagnosis to be treated with oncology treatment
Cancer site: bladder cancer, UTUC in the renal pelvis [right/left], UTUC in the ureter [right/left], urethral carcinoma
Type of treatment: neoadjuvant, induction, adjuvant, palliative
ECOG at start of treatment: 0,1,2,3,4
Included in clinical study: yes, no
Neoadjuvant treatment (start date, end date)
Type of treatment: ddMVAC, Cisplatin-Gemcitabine 3 week courses, Cisplatin-Gemcitabine 4 week courses, other
Number of courses: 1,2,3,4
Reason for terminating treatment: progression, side-effects, planned end, patients wish, patient deceased
Induction treatment (start date, end date)
Metastases: lymph nodes, liver, bone, brain, other
T stage T4b: Yes, no
Type of treatment: ddMVAC, Cisplatin-Gemcitabine 3 week courses, Cisplatin-Gemcitabine 4 week courses, other
Number of courses:1,2,3,4, 5,6,7,8,9,10,>10
Best treatment effect: complete response, partial response, stable disease, progressive disease, not applicable
Reason for terminating treatment: progression, side-effects, planned end, patients wish, patient deceased
Adjuvant treatment (start date, end date)
Type of treatment: ddMVAC, Cisplatin-Gemcitabine 3 week courses, Cisplatin-Gemcitabine 4 week courses, other
Number of courses:1,2,3,4,5,6,7,8,9,10,>10
Reason for terminating treatment: progression, side-effects, planned end, patients wish, patient deceased
Palliative treatment (start date, end date)
Date of confirmed metastatic disease
Metastatic sites: lymph nodes, liver, bone, lung, brain, other
Locally advanced disease T4b: yes, no
Hemoglobin level at start of treatment
Treatment line: 1,2,3,4,5,6
Re-challenge: yes, no
Type of treatment: ddMVAC, Cisplatin-Gemcitabine 3 week courses, Cisplatin-Gemcitabine 4 week courses, Gemcitabine, Gemcitabine-Carboplatin, Gemcitabine-Paklitaxel, Vinflunine, Pembrolizumab, Nivolumab, Atezolizumab, other
Number of courses:1,2,3,4, 5,6,7,8,9,10,>10
Best treatment effect: complete response, partial response, stable disease, progressive disease, unknown
Reason for terminating treatment: progression, side-effects, planned end, patients wish, patient deceased

ddMVAC=dose dense MVAC with GCSF

Table 8: Baseline data of UTUC in renal pelvis and their reference population in the BladderBaSe 2.0. For case individuals with cancer at both sides, only data from the first UTUC in renal pelvis diagnosis is included in the table.

		Cases (n total= 961)		Reference group (n total=4802)	
		N	%	N	%
Gender*	Men	601	63	3002	63
	Women	360	37	1800	37
Age at diagnosis/index date*	64 and below	156	16	782	16
	65-69	133	14	674	14
	70-74	228	24	1131	24
	75-79	231	24	1146	24
	80-84	151	16	750	16
	85 and above	62	6	319	7
Marital status	Unmarried/single	114	12	655	14
	Married/registered partners	529	55	2693	56
	Divorced/widowed	317	33	1454	30
	Missing	1	0		
Education level	Mandatory school	316	33	1547	32
	High school	410	43	1944	40
	University	220	23	1244	26
	Missing	15	2	67	1
Birth country	Sweden	820	85	4127	86
	Other nordic country	44	5	236	5
	Europe without nordic countries	61	6	281	6
	World outside Europe	36	4	158	3
	Missing				
Charlson Comorbidity Index**	No comorbidity (0)	419	44	3010	63
	Mild comorbidity (1)	101	11	643	13
	Intermediate comorbidity (2)	241	25	698	15
	Severe comorbidity (>2)	200	21	451	9
Drug Comorbidity Index***	Below 1.5	524	55	3275	68
	1.5 up to 3	252	26	868	18
	3 and above	185	19	659	14

Matching variables for reference group selection

**Calculated based on diagnoses recorded in the patient register within 10 years prior to diagnosis/index date

***Calculated based data on prescribed drugs according to Gedeberg et al[1] for patients with diagnosis/index date after 1 July 2006.

Table 9. Baseline data of UTUC in ureter and their reference population in the BladderBaSe 2.0. For case individuals with cancer at both sides, only data from the first UTUC in ureter diagnosis is included in the table.

		Cases (n total= 792)		Reference group (n total=3960)	
		N	%	N	%
Gender*	Men	514	65	2570	65
	Women	278	35	1390	35
Age at diagnosis/index date*	64 and below	95	12	472	12
	65-69	131	17	672	17
	70-74	183	23	890	22
	75-79	189	24	957	24
	80-84	128	16	636	16
	85 and above	66	8	333	8
Marital status	Unmarried/single	84	11	456	12
	Married/registered partners	430	54	2263	57
	Divorced/widowed	277	35	1238	31
	Missing	1	0	3	0
Education level	Mandatory school	288	36	1276	32
	High school	318	40	1554	39
	University	176	22	1085	27
	Missing	10	1	45	1
Birth country	Sweden	665	84	3401	86
	Other nordic country	35	4	172	4
	Europe without nordic countries	63	8	240	6
	World outside Europe	29	4	147	4
	Missing				
Charlson Comorbidity Index**	No comorbidity (0)	192	24	2441	62
	Mild comorbidity (1)	73	9	530	13
	Intermediate comorbidity (2)	275	35	570	14
	Severe comorbidity (>2)	252	32	419	11
Drug Comorbidity Index***	Below 1.5	366	46	2620	66
	1.5 up to 3	237	30	807	20
	3 and above	189	24	533	13

*Matching variables for reference group selection

**Calculated based on diagnoses recorded in the patient register within 10 years prior to diagnosis/index date

***Calculated based data on prescribed drugs according to Gedeberg et al[1] for patients with diagnosis/index date after 1 July 2006.

Table 10. Baseline data of urethral carcinoma and their reference population in the BladderBaSe 2.0

		Cases (n total= 146)		Reference group (n total=730)	
		N	%	N	%
Gender*	Men	121	83	605	83
	Women	25	17	125	17
Age at diagnosis/index date*	64 and below	18	12	90	12
	65-69	23	16	110	15
	70-74	32	22	166	23
	75-79	37	25	187	26
	80-84	18	12	87	12
	85 and above	18	12	90	12
Marital status	Unmarried/single	12	8	89	12
	Married/registered partners	87	60	414	57
	Divorced/widowed	47	32	227	31
	Missing				
Education level	Mandatory school	46	32	235	32
	High school	61	42	300	41
	University	36	25	184	25
	Missing	3	2	11	2
Birth country	Sweden	128	88	634	87
	Other nordic country	3	2	31	4
	Europe without nordic countries	13	9	44	6
	World outside Europe	2	1	21	3
	Missing				
Charlson Comorbidity Index**	No comorbidity (0)	20	14	427	58
	Mild comorbidity (1)	7	5	107	15
	Intermediate comorbidity (2)	57	39	110	15
	Severe comorbidity (>2)	62	42	86	12
Drug Comorbidity Index***	Below 1.5	68	47	451	62
	1.5 up to 3	38	26	169	23
	3 and above	40	27	110	15

*Matching variables for reference group selection

**Calculated based on diagnoses recorded in the patient register within 10 years prior to diagnosis/index date

***Calculated based data on prescribed drugs according to Gedeborg et al[1] for patients with diagnosis/index date after 1 July 2006.

References

1. Gedeberg, R., et al., *An aggregated comorbidity measure based on history of filled drug prescriptions - development and evaluation in two separate cohorts*. *Epidemiology*, 2021.